We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
GenScript Gencrispr™ Cas9 V1.1; 1mg
List Price
$1,025.00
Your Price
$1,025.00
GenScript Gencrispr™ Cas9 V1.11mg - GSCRPT (Additional S&H or Hazmat Fees May Apply)
NETA PART:
GSCRPT-Z03701-1
MFG.PART:
Z03701-1
UNSPSC:
12352204
Manufacturer:
GenScript USA Inc
Description
The GenCRISPR™ Cas9 v1.1 can be formed with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP complex to perform gene editing has been shown to reduce the challenges encountered with other CRISPR gene editing techniques such as viral and plasmid delivery. Challenges include off-target effects, cell viability and transcription/translational challenges. GenCRISPR™ Cas9 v1.1 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle nucleus localization signal (BPNLS) at both N-terminal and C-terminal. It has been reported that BPNLS is able to improve the gene editing efficiency. |
Note
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
Applications
| gRNA-dependent double-stranded DNA cleavage |
Properties
| Source | Recombinant Cas9 with a BPNLS at both N-terminal and C-terminal expressed by E.coli |
| Species | Streptococcus pyogenes |
| Tag | Tag-free |
| Molecular Weight | ~160 kDa |
| Concentration | 4 mg/ml |
| Active temperature | This Cas9 is active at 37 °C. |
| Formulation | Supplied as a solution of 25 mM Tris, 300 mM NaCl, 0.1 mM EDTA, 50% glycerol, pH 8.0. |
| Storage & Stability | This product remains stable for up to 12 months at -20 °C. Avoid repeated freeze-thaw cycles. |
| Key Features | High knockout efficiencies: Consistent high editing efficiency in in-vitro and in-vivo. Tag-free: No extra tag amino acid. DNA-free: No external DNA added to the system. |
Quality Control Specifications
| Appearance | Clear, colorless liquid |
| Purity | ≥ 90% as analyzed by SDS-PAGE |
| Concentration by A280 | 4 mg/ml±10% |
| Bioactivity (in vitro) | ≥ 90% |
| Residual DNase | Non-specific DNase activity |
| Residual RNase | Non-specific RNase activity |
| Endotoxin Level | ≤ 100 EU/mg as analyzed by gel clotting method |
Background
| References | 1. Liu, Xinyi, et al. "Improving editing efficiency for the sequences with NGH PAM using xCas9-derived base editors." Molecular Therapy-Nucleic Acids 17 (2019): 626-635. 2. Pollard, Victoria W., et al. "A novel receptor-mediated nuclear protein import pathway." Cell 86.6 (1996): 985-994. 3. Koblan, Luke W., et al. "Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction." Nature biotechnology 36.9 (2018): 843-846. |
| SKU | GSCRPT-Z03701-1 |
|---|---|
| Featured | No |
| Supplier Part Number | Z03701-1 |
| UM | EA |
| UNSPSC | 12352204 |
| Manufacturer | GenScript USA Inc |
| Temperature | This product remains stable for up to 12 months at -20 °C. Avoid repeated freeze-thaw cycles. |
| ProductLine | GSCRPT |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.000000 |
| Lead Time | 7 |
| Hazardous | N |
| Energy Star | No |
| Green | No |
| ACT Ecolabel | No |
| Controlled | N |